Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

431 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer.
Offersen BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Biete Sola A, Kirova YM, Pignol JP, Remouchamps V, Verhoeven K, Weltens C, Arenas M, Gabrys D, Kopek N, Krause M, Lundstedt D, Marinko T, Montero A, Yarnold J, Poortmans P. Offersen BV, et al. Among authors: poortmans p. Radiother Oncol. 2015 Jan;114(1):3-10. doi: 10.1016/j.radonc.2014.11.030. Epub 2015 Jan 24. Radiother Oncol. 2015. PMID: 25630428
The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups.
Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JH, Jager JJ, Pierart M, Poortmans PM, Struikmans H, Maat B, Van Limbergen E, Bartelink H. Vrieling C, et al. Among authors: poortmans pm. Radiother Oncol. 2000 Jun;55(3):219-32. doi: 10.1016/s0167-8140(00)00210-3. Radiother Oncol. 2000. PMID: 10869738 Clinical Trial.
The influence of the boost technique on local control in breast conserving treatment in the EORTC 'boost versus no boost' randomised trial.
Poortmans P, Bartelink H, Horiot JC, Struikmans H, Van den Bogaert W, Fourquet A, Jager J, Hoogenraad W, Rodrigus P, Wárlám-Rodenhuis C, Collette L, Pierart M; EORTC Radiotherapy and Breast Cancer Groups. Poortmans P, et al. Radiother Oncol. 2004 Jul;72(1):25-33. doi: 10.1016/j.radonc.2004.03.007. Radiother Oncol. 2004. PMID: 15236871 Clinical Trial.
The curative role of radiotherapy in adenocarcinoma of the prostate in patients under 55 years of age: a rare cancer network retrospective study.
Nguyen TD, Poortmans PM, van der Hulst M, Studer G, Pigois E, Collen TD, Belkacemi Y, Beckendorf V, Miralbell R, Scandolaro L, Soete G, Villa S, Gez E, Thomas O, Krengli M, Jovenin N. Nguyen TD, et al. Among authors: poortmans pm. Radiother Oncol. 2005 Dec;77(3):286-9. doi: 10.1016/j.radonc.2005.10.015. Epub 2005 Nov 22. Radiother Oncol. 2005. PMID: 16307812
Guidelines for primary radiotherapy of patients with prostate cancer.
Boehmer D, Maingon P, Poortmans P, Baron MH, Miralbell R, Remouchamps V, Scrase C, Bossi A, Bolla M; EORTC radiation oncology group. Boehmer D, et al. Among authors: poortmans p. Radiother Oncol. 2006 Jun;79(3):259-69. doi: 10.1016/j.radonc.2006.05.012. Epub 2006 Jun 22. Radiother Oncol. 2006. PMID: 16797094
Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882.
Antonini N, Jones H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, Fourquet A, Jager J, Hoogenraad W, Collette L, Pierart M, Hart G, Bartelink H. Antonini N, et al. Among authors: poortmans p. Radiother Oncol. 2007 Mar;82(3):265-71. doi: 10.1016/j.radonc.2006.09.014. Epub 2006 Nov 28. Radiother Oncol. 2007. PMID: 17126434 Clinical Trial.
Evidence based radiation oncology: breast cancer.
Poortmans P. Poortmans P. Radiother Oncol. 2007 Jul;84(1):84-101. doi: 10.1016/j.radonc.2007.06.002. Epub 2007 Jun 27. Radiother Oncol. 2007. PMID: 17599597 Review.
431 results